Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

Summary

Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer

Eligibility

Inclusion Criteria:

* Breast cancer patients diagnosed by pathology;

  * EOOG score is 0 or 1;

    * The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);

      ⑤ Previously received taxane chemotherapy for more than 6 months;

      ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;

      ⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
      * Accept regular follow-up visits; ⑨ There is complete pathological data available.

Exclusion Criteria:

* Non breast cancer patients;

  * Received electroacupuncture treatment within 6 months prior to the start of the study;

    * Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;

      * Prior to enrollment, there was a history of peripheral neuropathy;

        * Unstable heart disease or myocardial infarction within the first 6 months of the study;

          ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;

          ⑦ Uncontrolled epilepsy patients with uncontrolled seizures;

          ⑧ Merge with other malignant tumor patients;

          ⑨ Pregnancy and lactation period;

          ⑩ Refusal to join clinical trial patients

Conditions2

Browse More Trials